biological source
human lung
packaging
tube of 5 μg 96042331-DNA-5UG, pkg of vial of cells 96042331-1VL
growth mode
Aggregates in suspension
karyotype
Not specified
morphology
Not specified
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Drug-resistance studies
Biochem/physiol Actions
Human small cell lung cancer, drug-resistant
The drug-resistant cell line NCI-H69/LX10 has been derived from the parent line NCI-H69 (ECACC No 91091802). It is recommended to culture the cells without drug upon resuscitation; add doxorubicine once growth is fully established.
Preparation Note
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2, 37ºC; resuscitate in drug-free medium and add drug after growth has been established.
RPMI 1640 + 2mM Glutamine + 1.0 μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.